Johnson and Johnson ( Johnson and Johnson )

Johnson and Johnson

Johnson and Johnson's picture

Caring for the world, one person at a time... inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Employees of the Johnson & Johnson Family of Companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

Johnson and Johnson press release, blog etc

10/19/2017 - 04:46 Johnson & Johnson Medical GmbH to Acquire Surgical Process Institute
10/12/2017 - 20:36 JANSSEN ANNOUNCES U.S. FDA APPROVAL OF STELARA (USTEKINUMAB) FOR THE TREATMENT OF ADOLESCENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
10/11/2017 - 08:43 Janssen Submits New Drug Application to U.S. FDA for Apalutamide (ARN-509) to Treat Men with Non-Metastatic Castration-Resistant Prostate Cancer
10/05/2017 - 15:03 NAVIGATE ESUS Study Stopped Early Due to Comparable Efficacy in Treatment Arms
10/05/2017 - 02:52 Animas Corporation to Close Operations and Exit Insulin Pump Market
10/04/2017 - 16:40 CareAdvantage Perioperative Efficiency Capability Shown to Reduce Hospital Operational Costs and Improve Operating Room Efficiency
10/04/2017 - 12:10 NEW BREAST IMPLANT FOR PATIENTS UNDERGOING BREAST RECONSTRUCTION, AUGMENTATION OR REVISION SURGERY
10/02/2017 - 08:39 Janssen Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for INVOKANA (canagliflozin) to Reduce the Risk of Major Adverse Cardiovascular Events (MACE) Based on Landmark CANVAS Program
09/29/2017 - 13:41 Johnson & Johnson Advances Investigational Ebola Prime-boost Vaccine Regimen with New Partnership
09/27/2017 - 07:37 Health Systems Can Lower Operational Costs and Reduce Environmental Impact with CareAdvantage from the Johnson & Johnson Medical Devices Companies
09/22/2017 - 17:07 JANSSEN RECEIVES COMPLETE RESPONSE LETTER FROM U.S. FDA FOR SIRUKUMAB BIOLOGICS LICENSE APPLICATION
09/21/2017 - 12:32 Research Shows That Canadian Military Servicemembers and First Responders Struggle to Get Support for Their Own Health Needs
09/16/2017 - 08:32 NEW TWO-YEAR TREMFYA (GUSELKUMAB) DATA SHOW PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS ACHIEVED CONSISTENT RATES OF SKIN CLEARANCE
09/15/2017 - 15:58 JANSSEN RECEIVES CHMP POSITIVE OPINION FOR GUSELKUMAB RECOMMENDING APPROVAL FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN THE EUROPEAN UNION
09/15/2017 - 10:46 Johnson & Johnson Announces Collaboration with U.S. Department of Health and Human Services to Fight Influenza
09/13/2017 - 10:44 Johnson & Johnson Launches Dr. Paul Janssen Project to Catalyze and Convene Champions of Science Across Generations and Geographies
09/11/2017 - 08:25 Johnson & Johnson Consumer Inc. Debuts New Scientific Data at the European Academy of Dermatology and Venerology Annual Meeting
09/11/2017 - 06:29 Janssen to Discontinue Hepatitis C Development Program